Osimertinib 80 MG: A New Treatment Option for EGFR-Muted Non-Small Cell Lung Cancer
Osimertinib for the Treatment of EGFR Mutated Lung Cancer Non-small cell lung cancer (NSCLC) is the most commonly diagnosed type of lung cancer, accounting for about 80% of all lung cancer cases. EGFR-mutated NSCLC is a subtype of NSCLC caused by a genetic mutation in the epidermal growth factor receptor (EGFR) gene. This mutation allows […]
Osimertinib 80 MG: A New Treatment Option for EGFR-Muted Non-Small Cell Lung Cancer Read More »
